<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Moonlake Immunotherapeutics — News on 6ix</title>
    <link>https://6ix.com/company/moonlake-immunotherapeutics</link>
    <description>Latest news and press releases for Moonlake Immunotherapeutics on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sat, 28 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/moonlake-immunotherapeutics" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359a8b78dffbe2df10655f.webp</url>
      <title>Moonlake Immunotherapeutics</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics</link>
    </image>
    <item>
      <title>MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-week-40-results-from-its-phase-3-clinical-trials-of-sonelokimab-in-hidradenitis-suppurativa-at-the-2026-aad-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-week-40-results-from-its-phase-3-clinical-trials-of-sonelokimab-in-hidradenitis-suppurativa-at-the-2026-aad-annual-meeting</guid>
      <pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
      <description>Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve</description>
    </item>
    <item>
      <title>MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-positive-topline-results-from-its-phase-2-clinical-trial-of-sonelokimab-in-axial-spondyloarthritis-and-reports-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-positive-topline-results-from-its-phase-2-clinical-trial-of-sonelokimab-in-axial-spondyloarthritis-and-reports-2025-financial-results</guid>
      <pubDate>Sun, 22 Feb 2026 05:00:00 GMT</pubDate>
      <description>In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients</description>
    </item>
    <item>
      <title>ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/imagenebio-appoints-immunology-drug-development-veteran-dr-ben-porter-brown-as-chief-medical-officer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/imagenebio-appoints-immunology-drug-development-veteran-dr-ben-porter-brown-as-chief-medical-officer-1</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
      <description>Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced the appointment of</description>
    </item>
    <item>
      <title>MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-fda-fast-track-designation-sonelokimab-palmoplantar-pustulosis-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-announces-fda-fast-track-designation-sonelokimab-palmoplantar-pustulosis-0</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-positive-outcome-type-b-meeting-us-fda-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-positive-outcome-type-b-meeting-us-fda-and-0</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Announces Pricing of $75 Million  Underwritten Offering</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-pricing-75-million-underwritten-offering-2025-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-pricing-75-million-underwritten-offering-2025-0</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-third-quarter-2025-financial-results-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-third-quarter-2025-financial-results-and-0</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-week-16-results-vela-phase-3-hidradenitis-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-week-16-results-vela-phase-3-hidradenitis-0</guid>
      <pubDate>Sun, 28 Sep 2025 04:00:00 GMT</pubDate>
      <description>VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-second-quarter-2025-financial-results-and</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-second-quarter-2025-financial-results-and</guid>
      <pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
      <description>Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-0</guid>
      <pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-host-capital-markets-day-tuesday-april-29-2025-04-25-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-host-capital-markets-day-tuesday-april-29-2025-04-25-0</guid>
      <pubDate>Fri, 25 Apr 2025 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX),</description>
    </item>
    <item>
      <title>MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-secures-500-million-non-dilutive-financing-hercules-capital-and-announces-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-secures-500-million-non-dilutive-financing-hercules-capital-and-announces-0</guid>
      <pubDate>Thu, 03 Apr 2025 04:00:00 GMT</pubDate>
      <description>Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-full-year-2024-financial-results-and-provides-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-full-year-2024-financial-results-and-provides-0</guid>
      <pubDate>Wed, 26 Feb 2025 05:00:00 GMT</pubDate>
      <description>Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program</description>
    </item>
    <item>
      <title>MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-initiates-three-new-clinical-trials-and-further-expands-portfolio-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-initiates-three-new-clinical-trials-and-further-expands-portfolio-0</guid>
      <pubDate>Wed, 08 Jan 2025 05:00:00 GMT</pubDate>
      <description>New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS),</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-starts-phase-3-izar-program-nanobodyr-sonelokimab-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-starts-phase-3-izar-program-nanobodyr-sonelokimab-0</guid>
      <pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-third-quarter-2024-financial-results-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-third-quarter-2024-financial-results-and-0</guid>
      <pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash,</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-host-capital-markets-update-wednesday-september-11-2024-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-host-capital-markets-update-wednesday-september-11-2024-0</guid>
      <pubDate>Mon, 09 Sep 2024 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-second-quarter-2024-financial-results-and-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-reports-second-quarter-2024-financial-results-and-0</guid>
      <pubDate>Wed, 07 Aug 2024 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-positive-regulatory-feedback-both-fda-and-ema-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-announces-positive-regulatory-feedback-both-fda-and-ema-0</guid>
      <pubDate>Mon, 10 Jun 2024 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in</description>
    </item>
    <item>
      <title>MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa</title>
      <link>https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-starts-phase-3-vela-program-of-the-nanobodyr-0</link>
      <guid isPermaLink="true">https://6ix.com/company/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-starts-phase-3-vela-program-of-the-nanobodyr-0</guid>
      <pubDate>Thu, 16 May 2024 04:00:00 GMT</pubDate>
      <description>MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the</description>
    </item>
  </channel>
</rss>